美国CDC的研究指出,四个月后COVID-19疫苗加强针的功效会下降

2022-02-12 Allan MedSci原创

美国疾病控制和预防中心 (CDC) 本周五发布的新数据表明,COVID-19 疫苗加强针在大约四个月后会失去实质性功效,但它们似乎仍然可以为严重疾病提供强有力的保护。

美国疾病控制和预防中心 (CDC) 本周五发布的新数据表明,COVID-19 疫苗加强针在大约四个月后会失去实质性功效,但它们似乎仍然可以为严重疾病提供强有力的保护。

美国 CDC 建议所有 12 岁及以上的人在接种两剂辉瑞/BioNTech 的 Comirnaty 或 Moderna 的 Spikevax(两种基于 mRNA 的疫苗)后五个月,或在单剂强生公司的疫苗 Ad26.COV2.S 后两个月,接种 COVID-19 疫苗加强针。来自以色列和英国的初步数据暗示,加强疫苗的效力在几个月内会下降,但 CDC 的新发现提供了美国疫苗加强针效力减弱的第一个真实世界证据。

通过查看来自美国 10 个州的数据,调查人员估计了 Comirnaty 或 Spikevax 加强针在预防与 COVID-19 相关的急诊科和紧急护理中心就诊以及住院方面的效果。研究人员专注于 2021 年 8 月至 2022 年 1 月期间的数据,其中大部分时间 Delta 变体是主要菌株。

在 Omicron 占主导地位的时期,在第三剂疫苗后的两个月内,疫苗对 COVID-19 相关住院的有效性为 91%,但到第四个月下降至 78%。结果还表明,在防止前往紧急护理和急诊科的情况下,保护作用减弱更多,从第三剂后前两个月的 87% 下降到四个月后的 66%。至少五个月后,它下降到仅为 31%,但 CDC 警告说,这一发现“不准确,因为可用的数据很少”。

该机构表示,在 CDC 科学家分析的整个五个月期间,43% 的 COVID-19 疾病住院患者未接种疫苗,45% 接种了两剂疫苗,12% 接种了三剂疫苗。

 

原始出处:

https://firstwordpharma.com/story/5498345

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1193343, encodeId=b280119334344, content=疫苗后面还会继续要打, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b2b82397018, createdName=12346c4dm64暂无昵称, createdTime=Mon Feb 14 16:50:11 CST 2022, time=2022-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192921, encodeId=dd5f1192921ee, content=学习新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2716443372, createdName=ms300, createdTime=Sun Feb 13 11:43:08 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192830, encodeId=3262119283052, content=疫苗的确是隔一段就得加强, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b2b82397018, createdName=12346c4dm64暂无昵称, createdTime=Sat Feb 12 23:40:30 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192695, encodeId=e7b01192695b4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27fe6500495, createdName=ms2000002016332485, createdTime=Sat Feb 12 16:33:34 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192690, encodeId=1b95119269084, content=学习了 谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82d31990773, createdName=robbert123, createdTime=Sat Feb 12 16:13:09 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192682, encodeId=ccbe1192682bd, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ddff3357667, createdName=12ebd57em94暂无昵称, createdTime=Sat Feb 12 15:06:02 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192677, encodeId=693c11926e73b, content=疫苗接种还是需要的, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJrYTzfFXvZVHU61xgYmgdJuiciaMx2LVNUjSroKqamhtaWxWoHpc6IxIPZU1zHMXASvoia70eXBPiajg/132, createdBy=63712248731, createdName=tacuijian, createdTime=Sat Feb 12 14:47:53 CST 2022, time=2022-02-12, status=1, ipAttribution=)]
    2022-02-14 12346c4dm64暂无昵称

    疫苗后面还会继续要打

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1193343, encodeId=b280119334344, content=疫苗后面还会继续要打, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b2b82397018, createdName=12346c4dm64暂无昵称, createdTime=Mon Feb 14 16:50:11 CST 2022, time=2022-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192921, encodeId=dd5f1192921ee, content=学习新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2716443372, createdName=ms300, createdTime=Sun Feb 13 11:43:08 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192830, encodeId=3262119283052, content=疫苗的确是隔一段就得加强, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b2b82397018, createdName=12346c4dm64暂无昵称, createdTime=Sat Feb 12 23:40:30 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192695, encodeId=e7b01192695b4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27fe6500495, createdName=ms2000002016332485, createdTime=Sat Feb 12 16:33:34 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192690, encodeId=1b95119269084, content=学习了 谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82d31990773, createdName=robbert123, createdTime=Sat Feb 12 16:13:09 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192682, encodeId=ccbe1192682bd, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ddff3357667, createdName=12ebd57em94暂无昵称, createdTime=Sat Feb 12 15:06:02 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192677, encodeId=693c11926e73b, content=疫苗接种还是需要的, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJrYTzfFXvZVHU61xgYmgdJuiciaMx2LVNUjSroKqamhtaWxWoHpc6IxIPZU1zHMXASvoia70eXBPiajg/132, createdBy=63712248731, createdName=tacuijian, createdTime=Sat Feb 12 14:47:53 CST 2022, time=2022-02-12, status=1, ipAttribution=)]
    2022-02-13 ms300

    学习新知识

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1193343, encodeId=b280119334344, content=疫苗后面还会继续要打, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b2b82397018, createdName=12346c4dm64暂无昵称, createdTime=Mon Feb 14 16:50:11 CST 2022, time=2022-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192921, encodeId=dd5f1192921ee, content=学习新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2716443372, createdName=ms300, createdTime=Sun Feb 13 11:43:08 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192830, encodeId=3262119283052, content=疫苗的确是隔一段就得加强, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b2b82397018, createdName=12346c4dm64暂无昵称, createdTime=Sat Feb 12 23:40:30 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192695, encodeId=e7b01192695b4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27fe6500495, createdName=ms2000002016332485, createdTime=Sat Feb 12 16:33:34 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192690, encodeId=1b95119269084, content=学习了 谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82d31990773, createdName=robbert123, createdTime=Sat Feb 12 16:13:09 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192682, encodeId=ccbe1192682bd, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ddff3357667, createdName=12ebd57em94暂无昵称, createdTime=Sat Feb 12 15:06:02 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192677, encodeId=693c11926e73b, content=疫苗接种还是需要的, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJrYTzfFXvZVHU61xgYmgdJuiciaMx2LVNUjSroKqamhtaWxWoHpc6IxIPZU1zHMXASvoia70eXBPiajg/132, createdBy=63712248731, createdName=tacuijian, createdTime=Sat Feb 12 14:47:53 CST 2022, time=2022-02-12, status=1, ipAttribution=)]
    2022-02-12 12346c4dm64暂无昵称

    疫苗的确是隔一段就得加强

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1193343, encodeId=b280119334344, content=疫苗后面还会继续要打, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b2b82397018, createdName=12346c4dm64暂无昵称, createdTime=Mon Feb 14 16:50:11 CST 2022, time=2022-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192921, encodeId=dd5f1192921ee, content=学习新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2716443372, createdName=ms300, createdTime=Sun Feb 13 11:43:08 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192830, encodeId=3262119283052, content=疫苗的确是隔一段就得加强, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b2b82397018, createdName=12346c4dm64暂无昵称, createdTime=Sat Feb 12 23:40:30 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192695, encodeId=e7b01192695b4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27fe6500495, createdName=ms2000002016332485, createdTime=Sat Feb 12 16:33:34 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192690, encodeId=1b95119269084, content=学习了 谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82d31990773, createdName=robbert123, createdTime=Sat Feb 12 16:13:09 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192682, encodeId=ccbe1192682bd, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ddff3357667, createdName=12ebd57em94暂无昵称, createdTime=Sat Feb 12 15:06:02 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192677, encodeId=693c11926e73b, content=疫苗接种还是需要的, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJrYTzfFXvZVHU61xgYmgdJuiciaMx2LVNUjSroKqamhtaWxWoHpc6IxIPZU1zHMXASvoia70eXBPiajg/132, createdBy=63712248731, createdName=tacuijian, createdTime=Sat Feb 12 14:47:53 CST 2022, time=2022-02-12, status=1, ipAttribution=)]
    2022-02-12 ms2000002016332485

    学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1193343, encodeId=b280119334344, content=疫苗后面还会继续要打, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b2b82397018, createdName=12346c4dm64暂无昵称, createdTime=Mon Feb 14 16:50:11 CST 2022, time=2022-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192921, encodeId=dd5f1192921ee, content=学习新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2716443372, createdName=ms300, createdTime=Sun Feb 13 11:43:08 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192830, encodeId=3262119283052, content=疫苗的确是隔一段就得加强, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b2b82397018, createdName=12346c4dm64暂无昵称, createdTime=Sat Feb 12 23:40:30 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192695, encodeId=e7b01192695b4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27fe6500495, createdName=ms2000002016332485, createdTime=Sat Feb 12 16:33:34 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192690, encodeId=1b95119269084, content=学习了 谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82d31990773, createdName=robbert123, createdTime=Sat Feb 12 16:13:09 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192682, encodeId=ccbe1192682bd, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ddff3357667, createdName=12ebd57em94暂无昵称, createdTime=Sat Feb 12 15:06:02 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192677, encodeId=693c11926e73b, content=疫苗接种还是需要的, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJrYTzfFXvZVHU61xgYmgdJuiciaMx2LVNUjSroKqamhtaWxWoHpc6IxIPZU1zHMXASvoia70eXBPiajg/132, createdBy=63712248731, createdName=tacuijian, createdTime=Sat Feb 12 14:47:53 CST 2022, time=2022-02-12, status=1, ipAttribution=)]
    2022-02-12 robbert123

    学习了 谢谢

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1193343, encodeId=b280119334344, content=疫苗后面还会继续要打, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b2b82397018, createdName=12346c4dm64暂无昵称, createdTime=Mon Feb 14 16:50:11 CST 2022, time=2022-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192921, encodeId=dd5f1192921ee, content=学习新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2716443372, createdName=ms300, createdTime=Sun Feb 13 11:43:08 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192830, encodeId=3262119283052, content=疫苗的确是隔一段就得加强, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b2b82397018, createdName=12346c4dm64暂无昵称, createdTime=Sat Feb 12 23:40:30 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192695, encodeId=e7b01192695b4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27fe6500495, createdName=ms2000002016332485, createdTime=Sat Feb 12 16:33:34 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192690, encodeId=1b95119269084, content=学习了 谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82d31990773, createdName=robbert123, createdTime=Sat Feb 12 16:13:09 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192682, encodeId=ccbe1192682bd, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ddff3357667, createdName=12ebd57em94暂无昵称, createdTime=Sat Feb 12 15:06:02 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192677, encodeId=693c11926e73b, content=疫苗接种还是需要的, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJrYTzfFXvZVHU61xgYmgdJuiciaMx2LVNUjSroKqamhtaWxWoHpc6IxIPZU1zHMXASvoia70eXBPiajg/132, createdBy=63712248731, createdName=tacuijian, createdTime=Sat Feb 12 14:47:53 CST 2022, time=2022-02-12, status=1, ipAttribution=)]
    2022-02-12 12ebd57em94暂无昵称

    好文章

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1193343, encodeId=b280119334344, content=疫苗后面还会继续要打, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b2b82397018, createdName=12346c4dm64暂无昵称, createdTime=Mon Feb 14 16:50:11 CST 2022, time=2022-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192921, encodeId=dd5f1192921ee, content=学习新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2716443372, createdName=ms300, createdTime=Sun Feb 13 11:43:08 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192830, encodeId=3262119283052, content=疫苗的确是隔一段就得加强, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b2b82397018, createdName=12346c4dm64暂无昵称, createdTime=Sat Feb 12 23:40:30 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192695, encodeId=e7b01192695b4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27fe6500495, createdName=ms2000002016332485, createdTime=Sat Feb 12 16:33:34 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192690, encodeId=1b95119269084, content=学习了 谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82d31990773, createdName=robbert123, createdTime=Sat Feb 12 16:13:09 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192682, encodeId=ccbe1192682bd, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ddff3357667, createdName=12ebd57em94暂无昵称, createdTime=Sat Feb 12 15:06:02 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192677, encodeId=693c11926e73b, content=疫苗接种还是需要的, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJrYTzfFXvZVHU61xgYmgdJuiciaMx2LVNUjSroKqamhtaWxWoHpc6IxIPZU1zHMXASvoia70eXBPiajg/132, createdBy=63712248731, createdName=tacuijian, createdTime=Sat Feb 12 14:47:53 CST 2022, time=2022-02-12, status=1, ipAttribution=)]
    2022-02-12 tacuijian

    疫苗接种还是需要的

    0

拓展阅读

JAMA Netw Open:美国儿童群体接种COVID-19疫苗后可能的健康风险分析

在对较小儿童进行COVID-19疫苗接种后,需要对可能的健康风险保持警觉

Rheumatol Int:中国学者研究——COVID-19疫苗接种对风湿性疾病患者感染严重程度的影响

虽然COVID-19疫苗接种并未显著降低风湿病患者的COVID-19感染率,但接种疫苗显著减少了感染后出现肺炎和需要住院治疗的风险。

JNCI | COVID-19疫苗接种、感染和症状情况分析:美国癌症幸存者研究

该研究旨在全面了解美国癌症幸存者在新冠疫情期间的疫苗接种、感染和症状情况,癌症幸存者一旦感染COVID-19,更易出现中重度症状,需要针对这一脆弱人群制定COVID-19的预防和控制策略。

CGH:炎症性肠病患者接种COVID-19疫苗的长期效果和持久性

接种COVID-19疫苗可为绝大多数炎症性肠病成人患者(包括皮质类固醇使用者和老年人等脆弱人群)产生有效和持久的保护性反应。IBD患者可从COVID-19加强疫苗接种中获益。

AJOG:接种新冠肺炎疫苗后,更要警惕绝经后出血?

COVID-19疫苗的使用与新发绝经后出血诊断率增加无关。在接受COVID-19疫苗接种后的60天内,诊断为绝经后出血的情况很少见。

Journal of Hepatology:肝病患者和肝移植受者接种COVID-19疫苗后的免疫应答和临床结局

接种3种COVID-19疫苗后,肝病患者通常会对疫苗产生强大的抗体和T细胞应答,并表现为轻型COVID-19。然而,LTR持续无/低抗体滴度,似乎最易发生严重疾病。